PT - JOURNAL ARTICLE AU - Joseph McEvoy AU - Benjamin Carroll AU - Sanjay Gandhi AU - Avery Rizio AU - Stephen Maher AU - Mark Kosinski AU - Jakob Bjorner TI - Effect of Tardive Dyskinesia on Quality of Life: Patient-reported Symptom Severity is Associated with Deficits in Physical, Mental, and Social Functioning (P4.077) DP - 2018 Apr 10 TA - Neurology PG - P4.077 VI - 90 IP - 15 Supplement 4099 - http://n.neurology.org/content/90/15_Supplement/P4.077.short 4100 - http://n.neurology.org/content/90/15_Supplement/P4.077.full SO - Neurology2018 Apr 10; 90 AB - Objective: To investigate tardive dyskinesia (TD) burden on patients’ quality of life (QoL)Background: TD, an often-irreversible movement disorder typically caused by exposure to antipsychotics, most commonly affects the face, mouth, and tongue and may be debilitating. Due to the involuntary movements, patients with TD may experience increased feelings of stigma and decreased QoL compared with patients with psychiatric disorders who do not have TD.Design/Methods: Adults with clinician-confirmed schizophrenia, bipolar disorder, or major depressive disorder participated in an observational study. Approximately half (47%) of participants had a clinician-confirmed TD diagnosis. Participants completed the SF-12v2 Health Survey® (SF-12v2), Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF), social withdrawal subscale of the Internalized Stigma of Mental Illness scale (SW-ISMI), and rated the severity of their TD symptoms using the Committee for Clinical Research Side Effect Rating Scale (UKU-SERS). Group differences in SF-12v2 physical and mental component summaries (PCS and MCS), Q-LES-Q-SF, and SW-ISMI scores were analyzed.Results: TD (n=79) and non-TD (n=90) groups were similar in age, gender, and number of patients with schizophrenia, bipolar disorder, and major depressive disorder. TD patients reported significantly worse scores on PCS (P=0.003), Q-LES-Q-SF (P<0.001) and SW-ISMI (P<0.001) than non-TD patients. The difference in PCS exceeded the established minimal clinically important difference (MCID) of 3 points. When stratified by TD severity, those with more severe symptoms had significantly worse Q-LES-Q-SF (P<0.001) and SW-ISMI (P=0.006) scores than those with less severe symptoms. Differences in PCS (P=0.12) and MCS (P=0.089) based on TD severity were in the expected direction and exceeded the MCID.Conclusions: Among patients with psychiatric disorders, TD is associated with significant physical health burden. TD severity is also associated with lower overall QoL, greater social withdrawal, and deficits in both physical and mental health.Study Supported by:This study was funded by Teva Branded Pharmaceutical Products R&D, Inc. Petach Tikva, IsraelDisclosure: Dr. McEvoy has nothing to disclose. Dr. Carroll has nothing to disclose. Dr. Gandhi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries. Dr. Rizio has nothing to disclose. Dr. Maher has nothing to disclose. Dr. Kosinski has nothing to disclose. Dr. Bjorner has nothing to disclose.